Marijuana can lower eye pressure, which is the main risk factor for glaucoma, but the effect lasts only a few hours and comes with significant drawbacks that make it impractical as a treatment. The American Glaucoma Society’s position is clear: there is no evidence that medical cannabinoids are currently an effective treatment for improving eye pressure or preserving vision in glaucoma patients.
That said, the story is more nuanced than a simple yes or no. Here’s what actually happens when cannabinoids interact with your eyes, why the pressure drop isn’t as useful as it sounds, and what the future might hold.
THC Does Lower Eye Pressure, Briefly
THC, the psychoactive compound in marijuana, genuinely reduces intraocular pressure (the fluid pressure inside your eye that damages the optic nerve in glaucoma). Studies consistently show this effect. When taken orally, THC lowers eye pressure with a peak effect about two hours after dosing, but the reduction starts fading within four hours. Inhaled marijuana through smoking shows similar results.
Animal research has found that a single application of THC can lower eye pressure by roughly 28%, which sounds impressive. But that number comes from a controlled lab setting, and importantly, the effect was sex-dependent in mice, meaning it didn’t work equally across all subjects.
Why a Few Hours Isn’t Enough
Glaucoma is a 24-hour disease. Pressure inside your eye fluctuates throughout the day and night, and even spikes during sleep can cause damage over time. Standard glaucoma eye drops are designed to keep pressure consistently low with once- or twice-daily dosing. Marijuana’s short window of effect means you’d need to dose every three to four hours, around the clock, to maintain any meaningful pressure control.
That kind of schedule creates serious problems. Smoking or ingesting marijuana six to eight times per day would keep you continuously impaired, making it impossible to drive, work, or function normally. The required doses to achieve therapeutic eye pressure reduction tend to be high enough to produce strong psychoactive effects. As one review put it, achieving the necessary pressure-lowering effects “may require use of the most hallucinogenic ingredients in high doses.” On top of that, repeated dosing at this frequency leads to tolerance, meaning the pressure-lowering effect diminishes over time, and to systemic toxicity.
CBD Can Actually Make Things Worse
One of the most important findings for glaucoma patients to understand is that CBD, the non-psychoactive cannabinoid many people assume is the “healthy” part of marijuana, does not help with eye pressure. It may actively harm it.
A human study tested both THC and CBD in six glaucoma patients. A 5 mg dose of THC lowered eye pressure. A 20 mg dose of CBD had no effect at all. A 40 mg dose of CBD actually raised eye pressure. Animal studies confirmed this: CBD caused an elevation in eye pressure in mice. The FDA has flagged this as a concern, noting that the same research often cited to justify medical marijuana for glaucoma specifically showed CBD spiking pressure in the eye.
This matters because many CBD products are marketed with vague health claims, and someone with glaucoma might assume CBD eye drops or tinctures could help. They could potentially do the opposite.
How Standard Treatments Compare
Modern glaucoma medications are effective, well-tolerated, and require only one or two drops per day. Prescription eye drops can lower eye pressure by 20% to 35% depending on the class of medication, and they maintain that reduction around the clock. When drops aren’t enough, laser treatments and minimally invasive surgical procedures offer long-term pressure control without daily dosing at all.
Marijuana, by contrast, offers a comparable percentage drop in pressure but sustains it for a fraction of the day, requires constant re-dosing, impairs cognitive function, and builds tolerance. From a purely practical standpoint, it cannot compete with treatments designed specifically for the disease.
Cannabinoid Eye Drops Are in Development
The idea of getting THC’s pressure-lowering benefit without the psychoactive effects or short duration has driven research into cannabinoid-based eye drops. One company, Skye Bioscience, is testing a synthetic cannabinoid eye drop (SBI-100) designed specifically to activate the same receptor THC targets but through a formulation that penetrates eye tissue more effectively.
In preclinical trials across three different species, the topical formulation showed enhanced effectiveness and a longer duration of pressure lowering compared to THC itself. Early Phase 1 safety data in humans has been encouraging, with no serious adverse events and only mild side effects reported. This approach could eventually separate the useful pressure-lowering mechanism from the impractical aspects of whole-plant marijuana use, but it remains experimental.
The Bottom Line on Marijuana and Glaucoma
The idea that marijuana treats glaucoma has been circulating since the 1970s, and it’s rooted in a real biological effect. THC does lower eye pressure. But lowering pressure for a few hours while impairing your ability to function is not the same as treating a chronic disease that requires consistent, round-the-clock management for decades. Every major ophthalmology organization recommends against using marijuana as a glaucoma treatment. If you have glaucoma or are at risk, proven treatments exist that work far better with far fewer trade-offs.